OBJECTIVE: The primary objective of this study was to demonstrate the clinical and radiologic efficacy of 5 days compared with 7 days of gemifloxacin therapy in the treatment of acute bacterial rhinosinusitis (ABRS).
STUDY DESIGN: In this prospective, double-blind, multicenter, parallel-group study, adult patients presenting with ABRS were randomized to receive gemifloxacin 320 mg once daily for either 5 days (n = 218) or 7 days (n = 203).
RESULTS: For the primary efficacy end point, clinical response to therapy at follow-up, 5 days of therapy with gemifloxacin was as effective as 7 days of therapy (per-protocol population; treatment difference 0.44%; 95% confidence interval (CI), −6.54 to 7.41). Five and 7 days of treatment with gemifloxacin were well tolerated.
CONCLUSION AND SIGNIFICANCE: The clinical efficacy of gemifloxacin 320 mg daily for 5 days is at least as good as the efficacy of gemifloxacin 320 mg daily for 7 days in the treatment of ABRS.
Get full access to this article
View all access options for this article.
References
1.
Sinus and Allergy Health Partnership.Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Executive Summary. Otolaryngol Head Neck Surg2000;123(Suppl 1 part 2):S1–32.
2.
BrookI.Microbiology and management of sinusitis. J Otolaryngol1996;25:249–56.
3.
DoernGVPfallerMAKuglerKPrevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program. Clin Infect Dis1998;27:764–70.
4.
GwaltneyJMJrScheldWMSandeMAThe microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: A fifteen-year experience at the University of Virginia and review of other selected studies. J Allergy Clin Immunol1992;90:457–62.
5.
JacobsMRBajaksouzianSZillesASusceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US surveillance study. Antimicrob Agents Chemother1999;43:1901–8.
6.
FelminghamDGrjnebergRN and the Alexander Project Group. The Alexander Project 1996–1997: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother2000;45:191–203.
7.
SahmDFJonesMEHickeyMLResistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997–1998. J Antimicrob Chemother2000;45:457–66.
8.
LoweMNLambHM.Gemifloxacin. Drugs2000;59:1137–47.
9.
ChenDKMcGeerADe AzavedoJC, For the Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med1999;341:233–9.
10.
RittenhouseSMcCloskeyLBroskeyJIn vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens. J Antimicrob Chemother2000;45(suppl S1):23–7.
11.
DrlicaKZhaoX.DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev1997;61:377–92.
12.
MorrisseyIGeorgeJT.Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones. J Antimicrob Chemother2000;45(suppl S1):101–6.
13.
FergusonBJAnonJBHendrickKC, and the Gemifloxacin 009 Study Group. Efficacy of once daily gemifloxacin for 7 days compared with cefuroxime axetil twice daily for 10 days in the treatment of acute bacterial sinusitis. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17–20, 2000, Toronto, Canada.
14.
GehannoPPooleMDWaldER, and the Gemifloxacin 010 Study Group. Efficacy of 7 days of gemifloxacin in patients with acute bacterial sinusitis (ABS). Presented at the 3rd European Congress of Chemotherapy, May 7–10, 2000, Madrid, Spain.
15.
CockburnJReidALBowmanJAEffects of intervention on antibiotic compliance in patients in general practice. Med J Aust1987;147:324–5, 327–8.
16.
McCaigLFHughesJM.Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA1995;273:214–9.
17.
OkekeINLamikanraAEdelmanR.Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis1999;5:18–27.
18.
DaganRKlugmanKPCraigWAEvidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother2001;47:129–40.
19.
KingAMayJFrenchGComparative in vitro activity of gemifloxacin. J Antimicrob Chemother2000;45(suppl S1):1–12.
20.
McCloskeyLMooreTNiconovichNIn vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA. J Antimicrob Chemother2000;45(Suppl S1):13–21.
21.
HughesJMTenoverFC.Approaches to limiting emergence of antimicrobial resistance in bacteria in human populations. Clin Infect Dis1997;24(suppl 1):S131–5.
22.
OpalSMMayerKHMedeirosAA.Mechanisms of bacterial antibiotic resistance. In: MandellGBennettJDolinR, editors. Mandell Douglas and Bennett's principles and practice of infectious diseases. 5th ed.Philadelphia, PA: Churchill Livingstone; 2000. p. 236–53.
23.
SchragSJPenaCFernandezJEffect of short-course, high-dose amoxicillin therapy on resistant pneumococci carriage. JAMA2001;286:49–56.
24.
Barman BalfourJALambHM.Moxifloxacin: A review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs2000;59:115–39.
25.
BazMNJannettiWVillanuevaC, and the Sinusitis Infection Study Group. The efficacy and tolerability of moxifloxacin compared to trovafloxacin in the treatment of acute sinusitis. Today's Ther Trends1999;17:303–19.
26.
LangtryHDLambHM.Levofloxacin: Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Drugs1998;56:487–515.
AdelglassJDeAbateCAMcElvainePComparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute sinusitis in adults. Otolaryngol Head Neck Surg1999;120:320–7.
29.
AdelglassJJonesTMRuoffGA multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis. Pharmacotherapy1998;18:1255–63.
30.
BurkeTVillanuevaCMarianoHJr, and the Sinusitis Infection Study Group. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Clin Ther1999;21:1664–77.
31.
SiegertRGehannoPNikolaidisPA comparison of the safety and efficacy of moxifloxacin (BAY 12–8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. Respir Med (in press).
32.
HenkelTJMcKayDYoungC.Safety of gemifloxacin in adult patients with respiratory and urinary tract infections. Presented at the 3rd European Congress of Chemotherapy, May 7–10, 2000, Madrid, Spain.
33.
StahlmannRLodeH.Toxicity of quinolones. Drugs1999;58(Suppl 2):37–42.
